Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of TW-4752N vs rivastigmine in mild to moderate Alzheimer's disease
jRCT2031210496Phase 3Completed
- Sponsor
- Towa Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Towa Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline at 24 weeks in ADAS-Jcog. Started Dec 2021; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031210496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210496.